gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin complet construct gmp facil
highlight week januari januari buy announc complet construct
ancori compani new gmp facil pittsburgh pa facil anticip offici open
primari product site krystal phase i/ii gene therapi gt dystroph epidermolysi
bullosa deb food drug administr fda releas statement plan advanc cell
gene therapi releas includ fda plan add addit clinic review keep pace rapid
expans candid develop provid new seri clinic guidanc document avrobio
unrat announc fda clear investigator-sponsor ind applic ex vivo lentiviral-bas gt avr-
cystinosi advanc phase i/ii clinic trial expect dose patient
look forward januari januari januari phacilit leader world world stem cell
summit held miami fl confirm confer speaker includ repres adaptimmun
neutral privat yposkesi privat
weekli price move figur vivo genet medicin aav srna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
analyst taylor feehley phd moder kol call featur patent attorney discuss ip issu
microbiom medicin space issu may relev genet medicin buy
januari synthet biolog genet medicin kol call professor jame collin phd
analyst gbola amusa md cfa taylor feehley phd moder kol call featur dr jame collin
discuss emerg switch technolog synthet biolog tool genet medicin space
analyst gbola amusa md cfa moder panel pm entitl improv cell therapi via
gener technolog summit
march chardan sponsor gene therapi genom edit summit host orphan diseas
march chardan sponsor arm cell gene therapi investor day new york citi
april chardan sponsor arm meet mediterranean barcelona
gene express fda provid new gt guidelin recommend
januari fda commission scott gottlieb director center biolog evalu
research cber fda peter mark releas statement gear toward advanc develop cell
gene therapi help innov proactiv address potenti risk associ continu develop
new technolog space fda indic plan add addit individu review group
aid overse evalu cell gene therapi provid addit polici guidanc document
advanc cell gene therapi includ maxim use rmat design introduc
addit enforc action address product pose signific risk potenti harm curb
oper outsid regulatori complianc
pleas refer import disclosur inform regul analyst certif found page report
polici fda state plan seri clinic guidanc document relat differ area activ product
develop guidanc document includ recommend gt inherit blood disord
hemophilia gt certain neurodegen diseas fda note acceler approv pathway
may applic certain circumst paramet introduc manufactur innov car-
therapi without necessarili requir costli new clinic investig develop safe effect
cell-bas regen medicin product innov trial design research pool clinic data
follow common manufactur protocol aid biolog licens applic bla
year review highlight fda continu support promis cell gene therapi
agenc continu trend releas draft guidanc look continu regulatori support
develop
buy complet construct deb program manufactur facil januari
announc complet construct ancori new gmp manufactur facil pittsburgh
support clinic commerci manufactur phase i/ii asset gt deb
sq ft facil set offici open compani also announc plan build gmp
manufactur facil anticip complet support anticip commerci demand futur
genet medicin news januari januari
buy announc secondari public offer common stock rais mm januari
autl unrat sign leas futur manufactur site alexandria estat januari
wustl publish aav-bas gt approach block neurodegener mous model januari
buy complet construct gmp gt manufactur facil pittsburgh pa januari
sln gb unrat receiv ema orphan drug design iron overload disord januari
neutral appoint omar khwaja januari
fda state plan introduc new polici guidanc framework cell gt januari
amylon tx privat appoint art levin supervisori board add scientif advisori board januari
precis bioscienc privat appoint member scientif advisori board januari
arm releas initi list present compani cell gene meet januari
egenesi privat appoint paul sekhri presid ceo januari
unrat receiv fda clearanc ind applic gt cystinosi januari
unrat announc transit john mendlein advisori role effect februari januari
olix pharma unrat nomin sirna-bas candid geograph atrophi januari
obsidian tx privat collabor unrat celg dd technolog immunotherapi januari
compani mention report
page
page
select catalyst genet medicin coverag
provid follow-up data piib dose-confirm studi hemb
axo-lenti-pd report data first patient sunrise-pd phase i/ii trial
present data immun mechan action ovarian cancer
givosiran report top-line data envis piii trial acut hepat porphyria ahp
dcr-hbv initi clinic trial hepat viru pend cta approv
provid initi data phase trial tay-sachs/sandhoff diseas
provid top-line result phase rescu trial lhon
submit ind chronic wound
initi phase i/ii trial autosom recess congenit ichthyosi
report preliminari muscl biopsi result phase i/ii ignit dmd trial dmd
dcr-phxc initi phase ii/iii primari hyperoxaluria pend regulatori feedback
initi patient dose hope-b phase trial hemophilia hemb
file ind rett syndrom
provid program updat phase i/ii valen trial crigler-najjar syndrom
provid continu regulatori updat x-link myotubular myopathi xlmtm
aro-aat initi phase ii/iii studi liver diseas
zolgensma provid clinic data readout strong phase studi sma type
zolgensma anticip regulatori decis sma type
present updat clinic data xlmtm
provid program overview undisclos larg neuromuscular diseas
vy-aadc provid longer term data phase ib trial pd
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
report result piii revers trial result piii rescu trial lhon
file ind inherit amyotroph later sclerosi
file ind cta pomp diseas
complet enrol dose escal phase i/ii trial achm
complet enrol phase iia studi wet
resum enrol phase i/ii studi hofh
dose patient phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
optogenet candid collab w/ bionic sight file ind advanc retin diseas
 fc report plan interim readout phase trial rhgg
initi trial malign
complet phase i/ii gem studi dystroph epidermolysi bullosa deb
complet ind-en studi diseas
dose patient phase studi mp
zolgensma anticip approv eu
lumasiran initi illuminate-b -c phase trial
givosiran complet nda applic file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
provid prelim data phase i/ii patient defici
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
figur expect zolgensma approv price anticip broad implic vivo gt space
page
select catalyst genet medicin coverag
file ind pomp diseas
submit ema lhon
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
xlrp report interim data expans arm phase i/ii trial xlrp
file ind phase ii studi addit propos ophthalm indic
present interim data updat phase i/ii studi mp ii
present interim updat phase studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi phase trial dystroph epidermolysi bullosa deb
provid data interim analysi phase i/ii ignit dmd trial dmd
file ind ornithin transcarbamylas over-the-counter defici
provid initi data phase trial gangliosidosi
axo-aav-opmd initi clinic trial opmd phase specifi
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
dcr-hbv anticip first interim data clinic trial hbv
inclisiran report top-line data orion studi hypercholesterolemia
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
cemdisiran initi phase ii studi iga nephropathi
initi phase i/ii trial
zolgensma complet strong phase trial pre-symptomat sma type
initi clinic trial huntington diseas
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
report preliminari data phase i/ii studi batten diseas
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
initi phase i/ii studi best diseas
 file ind al huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
figur alnylam/mdco meira gtx nightstar solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
figur plan file bla aadc defici
report phase i/ii interim data mp ii worldsymposium
provid data updat phase ii trial fabri diseas
begin dose patient investigator-sponsor phase i/ii trial cystinosi
submit ind infantil batten diseas
report interim phase ii data recess dystroph epidermolysi bullosa
initi phase trial recess dystroph epidermolysi bullosa
 anticip data readout phase trial hd
initi phase ii trial multipl tumor type
begin patient dose phase trial
submit ind relapsed/refractori non-hodgkin lymphoma r/r nhl
aft spear cell report data phase trial hepatocellular carcinoma
initi clinic trial fanconi anemia use process product
initi phase dose escal studi danon diseas
submit ind gangliosidosi
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valoctocogen roxaparvovec valrox provid pi/ii data updat hem
valrox present full piii top-line data hem
valrox submit bla pend fda feedback hemophilia
bmn file ind phenylketonuria pku
provid dystrophin data phase trial dmd
provid interim dystrophin data preclin studi dma
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
ptc-fa file ind friedreich ataxia fa enter clinic
initi clinic trial charcot-marie-tooth type
lentiglobin initi phase studi sickl cell diseas
initi phase i/ii trial type gaucher diseas
file approv transit clinic trial platform manufactur
report data updat phase i/ii trial hemophilia
initi phase i/ii trial adult phenylketonuria
initi phase i/ii trial leukocyt adhes deficiency-i
rituximab report preliminari phase cohort expans data r/r nhl
sea-bcma report preliminari phase dose escal data r/r mm
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end januari vivo gm perform driven srna
page
week-over-week perform vivo genet medicin aav small rna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm nightstar genet rna therapytickerratingccm ptupsideclosechang changemc mm arcturu gene editingtickerratingccm ptupsideclosechang changemc mm intellia pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur small rna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy nite buy buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular askbio estev horama myonexu tamid
small rna therapi comp alnylam top pick srna gene therapi offer favor risk-reward dynam
corpor report factset chardan note mention stock unrat unless state target market cap uncov name rgl silenc model current market cap
figur select public small rna therapi companiesw prefer buy greater potenti drive upsid entir small rna space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat small rna therapi companiesadvirna silense sirnaom somagen sylentisnot adhera benitec biopharma addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida precis scienc recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
